Student Reseaerch Committee, Babol University of Medical Sciences, Babol, Iran.
Department of Pediatric, Faculty of medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Complement Ther Med. 2019 Aug;45:215-221. doi: 10.1016/j.ctim.2019.06.007. Epub 2019 Jun 17.
Since the treatment of gastroesophageal reflux disease (GERD) symptoms in children is of the utmost importance, the current study is aimed to evaluating the efficacy of quince syrup and ranitidine in the management of pediatric patients with symptomatic GERD.
This double-blind, randomized clinical trial was performed on 96 children suspected of suffering from GERD. The patients referred to the gastrointestinal clinic of Ghaem Hospital, Iran, during 2017. The participants were randomly categorized into two groups (ranitidine and ranitidine plus quince syrup). The GERD symptoms, including the severity and frequency of vomiting, refusal of eating, difficulty in swallowing, choking at the time of eating, burping or belching, and abdominal or belly pain, were gathered before and after the intervention (4 weeks) using standardized Global Severity Questionnaire (GSQ-YC).
The comparison of two groups in terms of vomiting, refusal of eating, burping or belching, and abdominal or belly pain showed a significant difference 4 and 6 weeks after the intervention (P< 0.05). However, the comparison of difficulty in swallowing and choking at the time of eating between the two groups showed that there was no significant difference after 2, 4, and 6 weeks of the intervention (P > 0.05). The comparison of the total scores between the two groups showed that there was a significant difference 2 (17.8 ± 2.6 vs 23.4 ± 4.0; P < 0.05), 4 (11.5 ± 2.3 vs 18.8 ± 3.6; P< 0.05), and 6 (12.2 ± 2.3 vs 21.1 ± 4.1; P< 0.05) weeks after the intervention.
The results showed that the administration of ranitidine plus quince syrup was useful to improve pediatric GERD. However, it is recommended to conduct the future studies with a larger sample size and different dosage.
由于治疗儿童胃食管反流病(GERD)症状至关重要,本研究旨在评估西洋梨糖浆和雷尼替丁在管理有症状的 GERD 儿科患者中的疗效。
这是一项双盲、随机临床试验,共有 96 名疑似患有 GERD 的儿童参与。这些患者于 2017 年被转诊到伊朗 Ghaem 医院的胃肠诊所。参与者被随机分为两组(雷尼替丁和雷尼替丁加西洋梨糖浆)。使用标准化的全球严重程度问卷(GSQ-YC)在干预前后(4 周)收集 GERD 症状,包括呕吐的严重程度和频率、拒食、吞咽困难、进食时呛咳、呃逆或嗳气,以及腹部或腹痛。
两组在干预后 4 周和 6 周时的呕吐、拒食、呃逆或嗳气和腹痛比较显示出显著差异(P<0.05)。然而,两组在吞咽困难和进食时呛咳的比较显示,干预后 2、4 和 6 周时无显著差异(P>0.05)。两组总评分的比较显示,在干预后 2 周(17.8±2.6 对 23.4±4.0;P<0.05)、4 周(11.5±2.3 对 18.8±3.6;P<0.05)和 6 周(12.2±2.3 对 21.1±4.1;P<0.05)时存在显著差异。
结果表明,雷尼替丁加西洋梨糖浆的给药有助于改善儿科 GERD。然而,建议进行未来的研究,样本量更大,剂量不同。